DiaMedica Therapeutics Inc
NASDAQ:DMAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
DiaMedica Therapeutics Inc
Other Current Assets
DiaMedica Therapeutics Inc
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
Other Current Assets
$645k
|
CAGR 3-Years
25%
|
CAGR 5-Years
34%
|
CAGR 10-Years
32%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Current Assets
$6.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
16%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Current Assets
$4B
|
CAGR 3-Years
31%
|
CAGR 5-Years
15%
|
CAGR 10-Years
6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Current Assets
$4.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Other Current Assets
$126.3m
|
CAGR 3-Years
20%
|
CAGR 5-Years
31%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Current Assets
$853.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
23%
|
CAGR 10-Years
21%
|
|
DiaMedica Therapeutics Inc
Glance View
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. The company is headquartered in Minneapolis, Minnesota and currently employs 14 full-time employees. The company went IPO on 2008-01-04. The firm is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The firm's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The firm also has other product pipelines for IgA Nephropathy and African Americans with CKD.
See Also
What is DiaMedica Therapeutics Inc's Other Current Assets?
Other Current Assets
645k
USD
Based on the financial report for Sep 30, 2025, DiaMedica Therapeutics Inc's Other Current Assets amounts to 645k USD.
What is DiaMedica Therapeutics Inc's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
32%
Over the last year, the Other Current Assets growth was 130%. The average annual Other Current Assets growth rates for DiaMedica Therapeutics Inc have been 25% over the past three years , 34% over the past five years , and 32% over the past ten years .
